Researchers find promising new approach to stop intestinal problems caused by immune cells

Bolstering a specific enzyme within the mitochondria of intestinal cells helped mitigate GI disease induced by T cells after bone marrow transplant, cancer immunotherapy.

10:19 AM

Author | Nicole Fawcett

microscopic colorful rainbow cells black background and yellow badge on bottom right and blue lettering saying lab notes
Images provided by Pavan Reddy, M.D.

When they are not fighting off diseases and infections, immune T cells can sometimes turn on the gastrointestinal system, causing problems such as autoimmune inflammatory bowel disease, graft-vs.-host disease from a bone marrow transplant or colitis from cancer immune checkpoint blocker therapies.

While traditional treatments for these conditions have focused on manipulating the immune system to mitigate these diseases, researchers at the University of Michigan Health Rogel Cancer Center took an entirely new approach.

"We asked whether there is anything intrinsic to the target intestinal cells themselves that gives them a greater ability to tolerate an attack from the immune cell," said Pavan Reddy, M.D., division chief of hematology/oncology and deputy director at the Rogel Cancer Center.

The team discovered a metabolic alteration within the intestinal epithelial cells that happens exclusively in these T cell-mediated gastrointestinal diseases. A series of experiments in seven different mouse models found that when an enzyme called SDHA is reduced, GVHD, IBD and immune checkpoint-related colitis got worse. SDHA levels were impacted only in the GI system and not in other organs.

The researchers also looked at several potential options to restore SDHA, including the metabolite butyrate, which Reddy's lab had previously identified as playing a role in the gut microbiome. More research is needed to understand how best to increase the level of SDHA, but it provides a promising target.

"Focusing on the target instead of the immune cells is an additional way to mitigate immune-mediated disease. This may take us away from suppressing the immune system, which often leads to infection," said study co-first author Keisuke Seike, Ph.D., a postdoctoral fellow in Reddy's lab.

Funding for this work was from National Institutes of Health grants HL090775, CA173878, CA203542, HL149633, K08HL130944, DK081943, DK89503 and CA46592; Japan Society for the Promotion of Science; the YASUDA Medical Foundation; the Kawasaki Foundation of Medical Science and Medical Welfare; the Ryobiteien Memorial Foundation; the MSD Life Science Foundation Public Interest Incorporated Foundation, the Okayama Medical Foundation, the SENSHIN Medical Research Foundation, the Kato Memorial Bioscience Foundation; and the NOVARTIS Foundation.

Paper cited: "Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology," Nature Immunology, DOI: 10.1038/s41590-021-01048-3

More Articles About: Lab Notes Cancer: Cancer Types Bone and Marrow Transplant (BMT) Cancer Research Rogel Cancer Center Cancer: Help, Diagnosis & Treatment Bone Marrow Transplant (BMT)
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories cancer cell blue yellow
Health Lab
Less chemoradiation is possible for some cancer patients
Some oropharynx cancer patients may qualify for less radiation treatments, according to a new study from experts at the University of Michigan Health Rogel Cancer Center.
Animated microscopic image of the glioblastoma's tumor microenvironment
Health Lab
New model of key brain tumor feature could help scientists understand how to develop new treatments
Model shows how oncostreams form and behave in brain tumors – and how to inhibit them
cancer cell blue yellow
Health Lab
Targeted drug shows promising ability in treating rare head and neck cancers
Experts at Rogel Cancer Center develop and study the impact of a new drug for salivary gland cancers
Health care provider with stethoscope holds patient's hand
Health Lab
Combatting prostate cancer stigma
Prostate cancer is highly treatable and over 98% of men survive 10 years if the cancer is diagnosed and treated early.
Woman in pink shirt lifts kettleball in an outdoor exercise class
Health Lab
How to make cancer prevention more equitable
Expert explains six behavioral risk factors for cancer and why current programs don’t always meet the needs of people from racially and ethnically minoritized groups and other vulnerable populations.
Portrait of Max Wicha, founding director of Rogel Cancer Center
Health Lab
‘We might for the first time really be thinking of cures of cancer’
Founding Rogel Cancer Center Director reflects on how cancer evolved from ‘the least scientific discipline’ to a shining example of how basic research discoveries can change clinical care.